MAO-inhibitors in Parkinson's Disease

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Monoamine oxidase inhibitors (MAO-I) are among the earliest treatments for Parkinson's disease (PD).
• Non-selective MAO-I have limited use in PD due to side effects, while selective MAO-A inhibitors are preferred for depression.
• Selective irreversible MAO-B inhibitors, selegiline and rasagiline, are recommended for treating PD symptoms like akinesia and motor fluctuations.

Purpose of the Study:

• To review the clinical use and potential of MAO-I in Parkinson's disease and other neurological conditions.
• To compare the efficacy, safety, and metabolic profiles of selegiline and rasagiline.
• To highlight the underappreciated role of MAO-I and explore innovative therapeutic strategies.

Main Methods:

• Review of existing literature on MAO-I in Parkinson's disease and depression.
• Comparison of pharmacological properties, metabolism, and clinical outcomes of selegiline and rasagiline.
• Discussion of neuroprotective and neurorestorative potentials of MAO-B inhibitors.

Main Results:

• Selective MAO-B inhibitors (selegiline, rasagiline) are safe and well-tolerated for PD treatment.
• Rasagiline demonstrates higher potency and a more favorable side effect profile compared to selegiline, attributed to its metabolism to aminoindan.
• Both selegiline and rasagiline exhibit neuroprotective and neurorestorative effects.

Conclusions:

• MAO-I, particularly selective MAO-B inhibitors, are valuable in managing PD and have potential as antidepressants and antidementia agents.
• Further research, including head-to-head trials, is needed to fully elucidate the clinical benefits and disease-modifying potential of MAO-I.
• Innovative combinations, such as MAO-I with acetylcholinesterase inhibitors or iron chelators, show promise for treating neurodegenerative diseases like Alzheimer's and PD.